PMID- 37829481
OWN - NLM
STAT- MEDLINE
DCOM- 20231101
LR  - 20231101
IS  - 2186-3326 (Electronic)
IS  - 0027-7622 (Print)
IS  - 0027-7622 (Linking)
VI  - 85
IP  - 3
DP  - 2023 Aug
TI  - Real-world effectiveness of ustekinumab for patients with ulcerative colitis: a 
      systematic review and meta-analysis.
PG  - 402-427
LID - 10.18999/nagjms.85.3.402 [doi]
AB  - Ustekinumab has recently been approved for the treatment of ulcerative colitis 
      (UC) based on data from clinical trials. However, the effectiveness of 
      ustekinumab in patients with UC in a real-world setting remains unclear. Hence, 
      in this meta-analysis, we aimed to evaluate the effectiveness of ustekinumab in a 
      real-world setting and to investigate the predictors of its effectiveness. A 
      comprehensive literature search was performed to examine the effectiveness of 
      ustekinumab in UC patients admitted between January 2019 and December 2021. Data 
      on clinical remission, response, and corticosteroid-free clinical remission rates 
      were extracted, pooled, and analyzed. Meta-regression analysis was performed to 
      investigate the source of heterogeneity and the impact of moderators on the 
      outcomes of interest. A total of 14 eligible studies were identified. The pooled 
      clinical remission rate was 55.0% at week 8, 36.1% at week 16, 46.6% at month 6, 
      and 38.6% at month 12. The meta-regression analysis showed that prior use of 
      anti-tumor necrosis factor (TNF) agents and vedolizumab and the publication style 
      were significant moderators. Additionally, out of 258 patients, there were 28 
      adverse events (AEs) (10.9%). The effectiveness of ustekinumab in real-world 
      patients with UC was consistent with the results clinical trials. Moreover, 
      previous treatment with anti-TNF agents and vedolizumab might have affected the 
      effectiveness of ustekinumab.
FAU - Uchida, Genta
AU  - Uchida G
AD  - Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Toyota, 
      Japan.
FAU - Nakamura, Masanao
AU  - Nakamura M
AD  - Department of Gastroenterology and Hepatology, Nagoya University Graduate School 
      of Medicine, Nagoya, Japan.
FAU - Yamamura, Takeshi
AU  - Yamamura T
AD  - Department of Gastroenterology and Hepatology, Nagoya University Graduate School 
      of Medicine, Nagoya, Japan.
FAU - Tsuzuki, Tomoyuki
AU  - Tsuzuki T
AD  - Department of Gastroenterology and Hepatology, Toyota Kosei Hospital, Toyota, 
      Japan.
FAU - Kawashima, Hiroki
AU  - Kawashima H
AD  - Department of Gastroenterology and Hepatology, Nagoya University Graduate School 
      of Medicine, Nagoya, Japan.
AD  - Department of Endoscopy, Nagoya University Hospital, Nagoya, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Japan
TA  - Nagoya J Med Sci
JT  - Nagoya journal of medical science
JID - 0412011
RN  - FU77B4U5Z0 (Ustekinumab)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Humans
MH  - *Ustekinumab/therapeutic use
MH  - *Colitis, Ulcerative/drug therapy/chemically induced
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - Treatment Outcome
MH  - Remission Induction
MH  - Tumor Necrosis Factor-alpha/therapeutic use
PMC - PMC10565585
OTO - NOTNLM
OT  - meta-analysis
OT  - systematic review
OT  - ulcerative colitis
OT  - ustekinumab
COIS- None declared.
EDAT- 2023/10/13 06:46
MHDA- 2023/11/01 12:43
PMCR- 2023/08/01
CRDT- 2023/10/13 04:04
PHST- 2022/07/01 00:00 [received]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2023/11/01 12:43 [medline]
PHST- 2023/10/13 06:46 [pubmed]
PHST- 2023/10/13 04:04 [entrez]
PHST- 2023/08/01 00:00 [pmc-release]
AID - 10.18999/nagjms.85.3.402 [doi]
PST - ppublish
SO  - Nagoya J Med Sci. 2023 Aug;85(3):402-427. doi: 10.18999/nagjms.85.3.402.